Koç University Metabolism and Cancer Laboratory

News

Innovative Research Targets Cancer-Related Muscle Wasting (From Koç University Annual Report 2023/2024)

Assistant Professor Dr. Serkan Kır and his team at Koç University’s Molecular Biology and Genetics Department have identified a key molecular mechanism behind cancer-associated muscle atrophy. Their groundbreaking research on the EDA2R/NIK signaling pathway, published in Nature, offers potential new therapeutic targets to counteract cachexia—a debilitating condition affecting nearly half of all cancer patients. Ongoing studies aim to develop treatments to suppress muscle loss in cancer patients.

Read More

New Research Publication: Tumour-induced Alterations in Single-nucleus Transcriptome of Atrophying Muscles

Our latest research article, “Tumour-induced alterations in single-nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism” is now published!  This study sheds light on the molecular mechanisms driving muscle atrophy in cancer cachexia. By analyzing single-nucleus transcriptomes from tumour-bearing mice, we discovered key gene signatures and pathways affected by tumour presence. Our findings pave the way for developing new therapeutics to combat muscle wasting in cancer patients.

Read More

New Publication: The Role of Interleukin‐6 Family Cytokines in Cancer Cachexia

We are thrilled to announce the publication of our latest research article in The FEBS Journal. Our study explores the critical roles of interleukin-6 family cytokines in the development of cancer cachexia. This wasting syndrome, affecting over half of all cancer patients, significantly impacts patient survival and quality of life. Our findings highlight the complex interactions of cytokines in promoting tissue wasting and suggest potential therapeutic targets for better clinical outcomes.

Read More

New Insights into Cancer Cachexia: The Role of EDA2R-NIK Signaling

We are excited to announce our latest review article, “EDA2R-NIK signaling in cancer cachexia,” exploring a novel signaling pathway contributing to muscle wasting in cancer patients. This groundbreaking research highlights the potential for new treatments targeting the EDA2R-NIK pathway to prevent muscle loss and improve patient outcomes. Stay tuned for more updates on this promising area of cancer research.

Read More

Exploring Science in Istanbul: A Conversation with Dr. Serkan Kır

In the article series ‘Science around the world’ featured in Trends in Molecular Medicine, they embark on a fascinating journey to discover the scientific insights and geographical influences shaping groundbreaking research. Today, they delve into Istanbul, Turkey, as Dr. Serkan Kır shares his experiences. Dr. Serkan Kır reflects on the unique opportunities and challenges encountered in Istanbul that have profoundly influenced his research.

Read More

New Research Highlights the Role of Oncostatin M in Cancer-Associated Muscle Wasting

Our lab is proud to announce our recent publication in Cell Reports Medicine, shedding light on a crucial mechanism behind muscle loss in cancer patients. This study, led by Aylin Domaniku-Waraich and team, demonstrates how Oncostatin M signaling can significantly impact muscle atrophy, presenting a potential target for therapeutic intervention. Understanding these pathways is vital for developing strategies to preserve muscle mass and function, ultimately improving patient outcomes. Read the full article to explore how this discovery could change the landscape of cancer treatment.

Read More

New Insights into Muscle Wasting Diseases: The Role of Ectodysplasin A2 Receptor Signaling

In the cutting-edge review “Ectodysplasin A2 Receptor Signaling in Skeletal Muscle Pathophysiology” by Sevgi Döndü Özen, groundbreaking insights reveal how EDA2R signaling is a key player in muscle wasting diseases, including cancer cachexia, muscular dystrophies, and ALS. This signaling pathway, involving the noncanonical NFκB and NFκB-inducing kinase (NIK), not only accelerates muscle atrophy and insulin resistance but also presents a promising target for therapeutic intervention. The article highlights the potential of targeting the EDA2R–NIK axis to combat muscle loss and improve metabolic functions, offering new hope for treatments that could revolutionize care for patients suffering from these debilitating conditions.

Read More